( Reuters) – Genetic screening specialist Qiagen ( QIA.DE) ought to have a targeted test for the coronavirus prepared this month and is exceptionally active in offering items to disease control institutions in China, its interim CEO said on Wednesday.
However while Qiagen could increase revenues by concentrating on products identifying the coronavirus it will continue to bet on development in its molecular diagnostics company, rather than unsure one-off gains, CEO Thierry Bernard told an outcomes teleconference.
The company headquartered in the Netherlands, which makes diagnostic packages for cancer and tuber